Zaloguj się

Gotowe bibliografie tematyczne / Metastatic carcinoma / Książki

Książki na temat „Metastatic carcinoma”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Metastatic carcinoma.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 19 lutego 2022

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 26 najlepszych książek naukowych na temat „Metastatic carcinoma”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Warner, Ellen. Phase I - II study of vinblastine and oral cyclosporin a in metastatic renal cell carcinoma. Ottawa: National Library of Canada, 1996.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

International, Symposium on Cellular Oncology (2nd 1985 Palm Springs Calif ). Occult nodal metastasis in solid carcinomata. New York: Praeger, 1987.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Oral cancer metastasis. New York: Springer, 2010.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Hoogewoud, H. M. Hepatocellular carcinoma and liver metastases: Diagnosis and treatment. Berlin: Springer-Verlag, 1993.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

McElligott, Anthony M. The role of matrix metalloproteinases and their inhibitors, the tissue inhibitors of metalloproteinases, in renal cell carcinoma cell invasion and metastasis. [S.l: The Author], 1999.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Surgical Treatment of Metastatic Renal Cell Carcinoma. Derman Tıbbi Yayıncılık, 2015. http://dx.doi.org/10.4328/derman.9786055121242.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

A, Stein Cy, i National Cancer Institute (U.S.). Office of Cancer Communications, red. Suramin, an active agent in metastatic adrenocortical carcinoma. [Bethesda, Md.?]: National Cancer Institute, Office of Cancer Communications, 1988.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Huang, William C., i Ezequiel Becher. Advanced and Metastatic Renal Cell Carcinoma an Issue of Urologic Clinics. Elsevier, 2020.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Calabrò, Fabio, i Cora N. Sternberg. Treatment of metastatic bladder cancer. Redaktor James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Pełny tekst źródła

Streszczenie:

Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.

Style APA, Harvard, Vancouver, ISO itp.

10

Massey, Veta Hamblen. RELATIONSHIP BETWEEN POWERLESSNESS, HARDINESS, DIAGNOSIS, AND HOPELESSNESS IN PERSONS HOSPITALIZED FOR CHOLECYSTECTOMY OR METASTATIC CARCINOMA. 1989.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Mano, Roy, i Ofer Yossepowitch. Adenocarcinoma of the bladder. Redaktor James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0081.

Pełny tekst źródła

Streszczenie:

Adenocarcinoma of the bladder accounts for 0.5–2 of bladder tumours. Risk factors include bladder exstrophy, bladder augmentation, schistosomiasis, and endometriosis. Bladder adenocarcinoma is classified as primary, arising from the bladder or urachal remnant, and secondary (metastatic). Most patients present with haematuria and irritative voiding symptoms. On imaging, a typical lesion is commonly located at the bladder dome. Compared to urothelial carcinoma (UC), most adenocarcinomas are diagnosed at high grade and advanced stage. Surgical treatment of localized disease entails partial cystectomy for urachal tumours and radical cystectomy for non-urachal or large urachal adenocarcinoma. The optimal treatment for metastatic disease has yet to be defined. Overall survival rates are 20–70% at 5 years, similar to those for UC, when adjusted for stage and grade. Secondary adenocarcinomas commonly arise from a genitourinary or gastrointestinal origin. Differentiation from primary tumours may be complex. Treatment depends on the prognosis of the primary cancer.

Style APA, Harvard, Vancouver, ISO itp.

12

1952-, Wick Mark R., red. Metastatic carcinomas of unknown origin. New York: DEMOS, 2008.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Keshav, Satish, i Palak Trivedi. Liver cancer. Redaktorzy Patrick Davey i David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0218.

Pełny tekst źródła

Streszczenie:

Primary hepatocellular carcinoma (HCC) arises from hepatocytes and is one of the commonest solid-organ malignancies in the world, particularly in the Far East and in sub-Saharan Africa. Cholangiocarcinoma arises from the biliary epithelium. The incidence is rising in the West, and primary sclerosing cholangitis (PSC) is an important risk factor (15% lifetime risk). Other forms of liver cancer include metastatic cancer, which is much more common in the West than any primary liver cancer, accounting for 90% of liver cancers and for which common primary sites are the colon, the stomach, the breasts, and the lungs; hepatoblastoma, which is an uncommon malignancy in children, originating from immature liver cell precursors; haemangiosarcomas, which are also rare, are malignant tumours arising from the blood vessels in the liver and can be very rapidly growing; and gall bladder cancer, arising from the gall bladder epithelium. Gallstones and PSC are risk factors for gall bladder cancer; in particular, PSC confers a risk >160 times that of the control population. This chapter primarily focuses on HCC.

Style APA, Harvard, Vancouver, ISO itp.

14

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Pełny tekst źródła

Streszczenie:

Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading >7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed where appropriate by surgery if there is a residual mass. Postoperative radiotherapy should be considered for women having more than one node involved with metastatic tumour at surgery. This must be balanced against the increased risk of lymphoedema where both surgery and radiotherapy are delivered to the groins. Chemoradiation using cisplatin or 5-FU/mitomycin C-based schedules has been reported but no randomized comparison with radiotherapy alone has been undertaken; whilst high response rates are seen there is a considerable increase in acute toxicity.

Style APA, Harvard, Vancouver, ISO itp.

15

Eisen, Tim. The patient with renal cell cancer. Redaktor Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Pełny tekst źródła

Streszczenie:

Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.

Style APA, Harvard, Vancouver, ISO itp.

16

Staehler, Gerd, i Luc P. Balant. Contemporary Research on Renal Cell Carcinoma: Basic and Clinical Developments. Springer, 2011.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

(Editor), C. G. Bollack, i D. Jacqmin (Editor), red. Basic Research and Treatment of Renal Cell Carcinoma Metastasis: Proceedings of an Eortc Genitourinary Group Meeting, Held in Strasbourg, France, Nove (Renal Cell Carcinoma Metastasis). Wiley-Liss, 1990.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Matin, Rubeta, Jane McGregor i Catherine Harwood. Skin cancer. Redaktorzy Patrick Davey i David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0259.

Pełny tekst źródła

Streszczenie:

Skin cancer is very common in the UK, and its incidence is rising rapidly. There are two broad classes of primary skin cancer: non-melanoma and melanoma. Non-melanoma skin cancer is the commonest form (100 000 cases diagnosed annually in the UK), accounting for nine out of ten skin cancers and includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Cutaneous melanoma is less common (10 000 cases diagnosed in the UK annually) but confers a significantly worse prognosis and accounts for 75% of skin cancer related deaths. There are also a number of other, rarer, non-melanoma skin cancers (e.g. appendageal carcinomas, Merkel cell carcinoma, sarcomas, vascular malignancies, and cutaneous lymphomas); however, these account for less than 1% of all skin cancers in the UK and so will not be specifically discussed in this chapter. Cutaneous metastases can occur secondary to any internal cancer or, indeed, to skin cancer (e.g. melanoma). In most cases, cutaneous metastasis occurs after the diagnosis of a primary cancer and usually in late stages of the disease but, in some cases, it may be the first presentation, in which case it should prompt a thorough investigation for the primary malignancy.

Style APA, Harvard, Vancouver, ISO itp.

19

Myers, Jeffrey. Oral Cancer Metastasis. Springer, 2014.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Seiichiro, Fujimoto, red. Paraaortic lymph node metastasis in gynecologic malignancies. Sapporo, Japan: Hokkaido University School of Medicine, 2000.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

G, Staehler, i Pomer S, red. Contemporary research on renal cell carcinoma: Basic and clinical developments. Berlin: Springer-Verlag, 1994.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

C, Bollack, Jacqmin D i European Organization for Research on Treatment of Cancer. Genito-Urinary Tract Cancer Cooperative Group., red. Basic research and treatment of renal cell carcinoma metastasis: Proceedings of an EORTC Genitourinary Group meeting, held in Strasbourg, France, November 4, 1988. New York: Wiley-Liss, 1990.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

(Editor), Moloy, i Ph.D Garth Nicolson (Editor), red. Occult Nodal Metastasis in Solid Carcinomata: Second International Symposium on Cellular Oncology (Cancer Research Monographs). Praeger Publishers, 1987.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

N, Chatzigeorgiou Konstantinos, i Bontis John N, red. Peritoneal carcinomatosis from ovarian cancer. New York: Nova Science Publishers, 2005.

Znajdź pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Prati, Raquel, i Olga Olevsky. Breast Cancer Staging and Treatment. Redaktorzy Christoph I. Lee, Constance D. Lehman i Lawrence W. Bassett. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190270261.003.0012.

Pełny tekst źródła

Streszczenie:

Breast carcinomas are a heterogeneous group of diseases that can be further characterized based on their histology, biomarkers, and molecular profiles. These characteristics, gathered during disease staging, provide crucial information with regard to treatment decisions. Staging has evolved from informing the operability of breast tumors to providing prognostic information, and consequently helping establish local and systemic treatment guidelines. This chapter provides a succinct overview of breast cancer staging and treatment. Topics covered include the histological classification of breast cancers, as well as classification by tumor size and location, lymph node involvement, and metastatic involvement. The topic of molecular assays for prognostic information is reviewed. Finally, current treatment paradigms, including surgery, radiation, and chemotherapy regimens for different types of breast cancer, are discussed.

Style APA, Harvard, Vancouver, ISO itp.

26

Prasad, Raj K., i Imeshi Wijetunga. Hepatobiliary surgery (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198749813.003.0002.

Pełny tekst źródła

Streszczenie:

This chapter discusses common elective and emergency presentations to hepatobiliary surgery. Gallstone disease, being the commonest hepatobiliary condition encountered by general surgical trainees, is discussed in detail. A separate section on acute ascending cholangitis is included with a brief description of the steps involved in laparoscopic cholecystectomy. Acute pancreatitis is discussed in Pancreatic Surgery Chapter 3. An overview of the assessment and management of post-cholecystectomy complications, such as bile duct injury and vascular injuries, is provided with illustrations. Management of common malignant conditions of the liver, such as colorectal liver metastasis, hepatocellular carcinoma, and cholangiocarcinoma, is included with detailed discussion of pre-operative imaging. Liver resection surgery and liver transplant surgery, as well as non-surgical management, are discussed. Details of post-operative management of hepatobiliary patients are aimed at the junior surgical trainee working in a tertiary hepatobiliary unit to aid day-to-day management of post-operative patients on the wards, as well as subsequent follow-up.

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!